Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELA-070 in healthy adult smokers
NCT03148925Phase 1Completed
- Sponsor
- Selecta Biosciences
- Start
- May 2017
- Primary completion
- Oct 2018
- Modality
- Nanoparticles, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SELA-070 in Tobacco Use Disorder (TUD), sponsored by Selecta Biosciences. Primary endpoint: Adverse Events at 21 weeks. Started May 2017; status: completed.
02
Drugs
SELA-070
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT03148925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03148925.